Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Paclitaxel 134Carboplatin 129Bevacizumab 86Gemcitabine 45pembrolizumab 37olaparib 33Cisplatin 30liposomal doxorubicin 29Docetaxel 29Cyclophosphamide 29Topotecan 28niraparib 27Taxes 20Etoposide 18Filgrastim 16Doxorubicin 16Immunoglobulin G 15Disulfides 15apatinib 12Letrozole 12Albumin-Bound Paclitaxel 12Drug Therapy 11fluzoparib 10fludarabine 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 10durvalumab 9Nivolumab 9pazopanib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasms × senaparib × Clear all
NCT04089189 2026-01-28

SABRINA

Impact Therapeutics, Inc.

Phase 2 Completed
93 enrolled
Gynecologic

Ovarian Neoplasms

NCT06617923 2025-10-27

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡